Samer Kebbeh, MD
General Practice · Loma Linda, CANPI 1922629112
Payments from drug & device makers
Across 342 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$961
- Biogen$879
- Novartis$736
- AstraZeneca$624
- EMD Serono, Inc.$448
- Pfizer$393
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,08798%
- Education$1082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $961 |
| Biogen | 37 | $879 |
| Novartis | 51 | $736 |
| AstraZeneca(2 entities) | 15 | $624 |
| EMD Serono, Inc. | 10 | $448 |
| Pfizer | 19 | $393 |
| Lundbeck LLC | 14 | $348 |
| SK Life Science, Inc. | 25 | $321 |
| Argenx US, Inc. | 11 | $293 |
| Amneal Pharmaceuticals LLC | 11 | $287 |
| UCB, Inc. | 11 | $278 |
| Amgen | 9 | $246 |
| Eisai Inc. | 7 | $178 |
| Otsuka America Pharmaceutical, Inc. | 12 | $155 |
| Genentech USA, Inc. | 4 | $118 |
| Livanova USA, Inc. | 5 | $116 |
| Neurocrine Biosciences, Inc. | 3 | $110 |
| Lilly USA, LLC | 4 | $82 |
| Teva Pharmaceuticals USA, Inc. | 3 | $74 |
| Impel Pharmaceuticals Inc. | 1 | $63 |
| Tonix Medicines, Inc. | 3 | $58 |
| Forte Bio-pharma LLC | 3 | $55 |
| MDD US Operations, LLC | 3 | $51 |
| Merz Pharmaceuticals, LLC | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Noven Therapeutics, LLC | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| TG Therapeutics, Inc. | 1 | $31 |
| Johnson & Johnson | 1 | $29 |
| Octapharma USA, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Harmony Biosciences LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,195 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rasagiline Mesylate | 18 | $2,612 |
| Donepezil Hcl | 57 | $548 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 25 | $498 |
| Gabapentin | 29 | $168 |
| Memantine Hcl | 19 | $124 |
| Duloxetine Hcl | 11 | $108 |
| Meclizine Hcl | 16 | $83 |
| Meloxicam | 28 | $23 |
| Atorvastatin Calcium | 12 | $15 |
Paid to pharmacies, not to this prescriber.
Other general practice in Loma Linda
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.